Development of plasma-based coating processes for medical devices with tailored-range bactericidal properties

开发具有定制杀菌性能的医疗器械等离子涂层工艺

• 批准号: 549867-2020
• 负责人: Mantovani, DiegoD
• 金额: $ 12.67万
• 依托单位: Université Laval
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=753942
• 关键词: Development; plasma; based; coating; processes

Central venous catheters (CVCs) are vital for many applications in medicine, especially for critical care and cancer patients. The use of CVC is associated with risk of microbial contamination in the form of a central venous catheter-related blood stream infection (CVC-BSI), which can occur during their implantation or manipulation. CVC-BSI represent a major global health care challenge. Prevention of CVC-BSI are based on biofilm prevention and on the release of antibacterial agents to overcome bacterial proliferation. The most common and successful approaches include bulk modification techniques or surface approaches, such as physical (plasma) or chemical (grafting by plasma, gamma radiation, corona or laser). In this light, the hereby presented project proposes the development of a procedure for the fabrication of an antiadhesive, antibacterial and hemocompatible coatings, based on plasma enhanced chemical vapour deposition (PECVD). The planned surface modification of implantable CVCs will provide a relevant advancement to tackle the expensive nosocomial infection problems, which are responsible for a relevant increase of the hospitalization costs and clinical complications, up to mortality rate of 17% in patients affected by a CVC-BSI, estimated at 40% in Brazil. The planned surface modification strategies foresee the controlled release of metallic ions, embedded in different proposed architectures of multifunctional thin films; they will be deposited on silicone surfaces, and they will be optimized for tubular geometries. The here proposed approach is based on a collaborative research and development strategy involving the Laboratory for Biomaterials and Engineering of Laval University, with its world-renowned expertise in biomedical material and plasma surface treatments, Plasmionique Inc., an established Canadian company, devoted to plasma processes for industrial and research purposes, and IBEG, the leader catheters manufacturer in Brazil. The presented workplan foresees the participation of a network of clinicians, industrials and academic collaborators, to maximize the final impact on the introduced innovation element of CVC-BSI on the Canadian and global market.

中央静脉导管（CVC）对于许多在医学中的应用至关重要，尤其是对重症监护和癌症患者。 CVC的使用与中央静脉导管相关血流感染（CVC-BSI）形式的微生物污染的风险有关，这可能在其植入或操纵期间发生。 CVC-BSI代表了全球主要的医疗挑战。 CVC-BSI的预防基于预防生物膜和释放抗菌剂以克服细菌增殖。最常见和成功的方法包括散装修饰技术或表面方法，例如物理（等离子体）或化学方法（血浆，伽马辐射，电晕或激光）。在这个角度，基于血浆增强的化学蒸气沉积（PECVD），提出的项目提出了制造抗粘附性，抗菌和血液相容性涂料的程序的开发。计划进行的可植入CVC的表面修饰将提供相关的进步，以解决昂贵的医院感染问题，这些问题是导致住院成本和临床并发症相关的增加，在巴西估计为40％的CVC-BSI患者中，受CVC-BSI影响的患者的死亡率高达17％。计划的表面修饰策略预见了金属离子的受控释放，并嵌入了多功能薄膜的不同构造中；它们将沉积在有机硅表面上，并将针对管状几何形状进行优化。此处提出的方法基于一项合作研究和发展策略，该战略涉及Laval University的生物材料和工程实验室，其世界知名的生物医学材料和血浆表面处理方面的专业知识，Plasmionique Inc.是一家既定的加拿大公司，致力于工业和研究目的的等离子体过程，以及Ibegs Sanufation，是针对工业和研究目的的等离子体过程。提出的工作计划预测，临床医生，工业和学术合作者网络的参与，以最大程度地影响CVC-BSI对加拿大和全球市场的创新元素的最终影响。